Skip to main content
. 2019 Jul 11;20(14):3403. doi: 10.3390/ijms20143403

Figure 3.

Figure 3

Diprovocim (TLR1/TLR2 agonist) acts in combination with anti-PD-L1 to cause tumour cell lysis, leading to a 100% survival rate in mice. Anti-PD-L1 decreases the inhibition of immune cells to allow an unrestrained response against tumours. Diprovocim increases antigen presentation and cytokine release, increasing immune cell proliferation [63].